The primary endpoint of this randomized, double-blind, placebo-controlled, descriptive trial was change in relative QLF score, which uses high resolution CT imaging to measure the extent of lung fibrosis (thickening and scarring of the lungs), from baseline to 6 months of treatment.
The study showed a reduction in the development of lung fibrosis among people treated with Ofev, as measured by quantitative lung fibrosis (QLF) score. Lower QLF scores indicate less fibrotic progression in the lung.
In this study, the QLF score from baseline to 6 months was 11.4% in people treated with Ofev versus 14.6% in the placebo group (difference 3.2%, exploratory endpoint not statistically significant).
A secondary endpoint of the trial was absolute mean change in forced vital capacity (FVC), a measure of lung function.
At baseline, mean FVC was 2997 mL among people treated with Ofev and 2921 mL among people on placebo. The adjusted mean absolute changes in FVC from baseline to month 6 were −14.2 mL and −83.2 mL in the Ofev and placebo groups, respectively.
The US Food and Drug Administration approved Ofev for the treatment of idiopathic pulmonary fibrosis on October 15, 2014. Ofev is one of the first FDA-approved drug treatments for IPF and the only known kinase inhibitor approved to treat this disease.
Boehringer Ingelheim Pharmaceuticals is the largest US subsidiary of Boehringer Ingelheim Corp., headquartered in Ingelheim, Germany. The company operates globally with approximately 50,000 employees in three business areas including human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review